Boryung to foster Astrix for a public healthcare drug

Published: 2005-07-21 06:59:00

Updated: 2005-07-21 06:59:00

Boryung has adopted a marketing strategy for "Astrix" (a drug for thrombosis) to be fostered as a public healthcare remedy. Astrix is a 100mg low dosed aspirin preparation for the prevention of cardiovascular disorders with an excellent safety profile for a long term administration, currently mar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK